Health-care stocks fell due to concerns over AbbVie and Humana. AbbVie's shares dropped by over 12% following disappointing results from its schizophrenia drug trials. Conversely, Bristol Myers' stock rose by around 10% due to reduced fears of competition for its Cobenfy franchise.